Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal transduction pathways, which have led to the ...
Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as ... Clinical stage 1 non-Hodgkin's lymphoma: long- term follow-up of patients treated by the British National Lymphoma Investigation with ...
Powhatan's Mantle: Indians in the Colonial Southeast, Revised and Expanded Edition The Calumet Ceremony in the Southeast as Observed Archaeologically ian w. brown There remains no more, except to speak of the Calumet. There is nothing more mysterious or more respected among them. Less honor is...
Risk factor adapted treatment of Hodgkin's lymphoma in childhood: strategies and results of three consecutive multicenter studies in the Federal Republic of Germany Recent Results in Cancer Re- search 117:205-213, 1989.Schellong G, Hirnig 1, Schwarze EW, et al: Risk factor adapted treatment ...
Credit: Pixabay/CC0 Public Domain Treatment advances have improved the survival of individuals with Hodgkin lymphoma (HL)—a type of cancer that affects the lymphatic system—but therapies can increase patients' risk of developing heart problems. A recent study published by Wiley online inCANCERrevea...
Background: Survival rates in patients (pts) with classic Hodgkin lymphoma (HL) aged ≥60 years (y) are lower than younger pts. The difference is due to comorbidities, impaired performance status, decreased chemotherapy tolerance, and increased treatment-related toxicity and mortality. The frontline...
Involved-field radiotherapy in patients with stage III/IV Hodgkin’s lymphoma: first results of the randomised EORTC trial # 20884 Author links open overlay panelB.M.Aleman12J.M.Raemaekers2M.Henry-Amar2A.Pinna2T.Girinsky2M.L.Lybeert2J.H.Meerwaldt2J.Thomas2U.Tirelli2A.M.Mandard2Show more ...
TREATMENT RESULTS FOR STAGE I AND II NON-HODGKIN'S LYMPHOMAS OF THE HEAD AND NECK from 1969 to 1987. The 5 year survival rates of primary Waldeyer's ring lymphoma according to stage were 72.7% of stage I and 58.9% of stage II. ... T Akimoto,F Wakao,I Tsukiyama,... - 《Journal ...
The role of bleomycin and dacarbazine in the ABVD regimen (ie, doxorubicin, bleomycin, vinblastine, and dacarbazine) has been questioned, especially for treatment of early-stage favourable Hodgkin's lymphoma, because of the drugs' toxici... K Behringer,H Goergen,F Hitz,... - 《Lancet》 被...
Adding chemotherapy to radiotherapy regimens can increase response and relapse-free survival in patients with Hodgkin lymphoma (HL) who have an unfavorable prognosis; however, the poorer prognosis of older patients and their decreased tolerance of chemotherapy means that this group is usually initially ...